Reuters logo
BRIEF-Novo Nordisk gets EU approval for haemophilia drug
June 6, 2017 / 3:02 PM / 4 months ago

BRIEF-Novo Nordisk gets EU approval for haemophilia drug

June 6 (Reuters) - Novo Nordisk

* Says the European Commission has granted marketing authorisation for Refixia for treatment of adolescents and adults with haemophilia B

* Says expects to launch Refixia in the first European countries in the fourth quarter of 2017 Source text for Eikon: Further company coverage: (Copenhagen newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below